MedTrace Logo

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

NCT02265679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-10-16

No results posted yet for this study

Summary

Safety, tolerability and pharmacokinetics following single doses

Conditions

Interventions

DRUG

BIIL 284 BS, low dose, pediatric patients

DRUG

BIIL 284 BS, medium dose, pediatric patients

DRUG

BIIL 284 BS, high dose, pediatric patients

DRUG

BIIL 284 BS, low dose, adult patients

DRUG

BIIL 284 BS, medium dose, adult patients

DRUG

BIIL 284 BS, high dose, adult patients

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2002-07-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265679 on ClinicalTrials.gov